Literature DB >> 17687268

The paracrine hormone hypothesis of colorectal cancer.

G M Pitari1, P Li, J E Lin, D Zuzga, A V Gibbons, A E Snook, S Schulz, S A Waldman.   

Abstract

Colorectal carcinogenesis originates in the context of dysregulated epithelial cell homeostasis, wherein hyperproliferation, hypodifferentiation, metabolic reprogramming, and mesenchymal remodeling reflect recursive mutually reinforcing mechanisms contributing to progressive genomic instability. Although genotypic and phenotypic elements characterizing the terminal integration of these pathophysiological processes defining cancer are well enumerated, events initiating, coordinating, and sustaining this hierarchical maladaptive systems evolution remain elusive for most tumors. In the intestine, guanylyl cyclase C (GCC) and its paracrine ligands organize and regulate the homeostatic integrity of the crypt-villus axis, forming a hormonal tumor suppressor signaling sequence, whose dysfunction defines the initiation of neoplastic transformation and creates a permissive niche for tumor progression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17687268     DOI: 10.1038/sj.clpt.6100325

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  39 in total

1.  Molecular staging estimates occult tumor burden in colorectal cancer.

Authors:  Alex Mejia; Stephanie Schulz; Terry Hyslop; David S Weinberg; Scott A Waldman
Journal:  Adv Clin Chem       Date:  2010       Impact factor: 5.394

2.  Sex modulates intestinal transformation by the tumor-suppressor GCC.

Authors:  Peng Li; Stephanie Schulz; Giovanni M Pitari; Scott A Waldman
Journal:  Clin Transl Sci       Date:  2008-09       Impact factor: 4.689

3.  Sex modulates intestinal transformation by the tumor-suppressor GCC.

Authors:  Peng Li; Stephanie Schulz; Giovanni M Pitari; Scott A Waldman
Journal:  Clin Transl Sci       Date:  2008-09       Impact factor: 4.689

4.  Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes.

Authors:  Terry Hyslop; David S Weinberg; Stephanie Schulz; Alan Barkun; Scott A Waldman
Journal:  Cancer       Date:  2011-09-01       Impact factor: 6.860

Review 5.  Molecular staging individualizing cancer management.

Authors:  Alex Mejia; Stephanie Schulz; Terry Hyslop; David S Weinberg; Scott A Waldman
Journal:  J Surg Oncol       Date:  2012-04-01       Impact factor: 3.454

Review 6.  Guanylyl cyclase C as a biomarker in colorectal cancer.

Authors:  Terry Hyslop; Scott A Waldman
Journal:  Biomark Med       Date:  2013-02       Impact factor: 2.851

Review 7.  Immunotherapeutic strategies to target prognostic and predictive markers of cancer.

Authors:  Michael S Magee; Adam E Snook; Glen P Marszalowicz; Scott A Waldman
Journal:  Biomark Med       Date:  2013-02       Impact factor: 2.851

Review 8.  GCC signaling in colorectal cancer: Is colorectal cancer a paracrine deficiency syndrome?

Authors:  P Li; J E Lin; G P Marszlowicz; M A Valentino; C Chang; S Schulz; G M Pitari; Scott A Waldman
Journal:  Drug News Perspect       Date:  2009 Jul-Aug

9.  Receptor guanylyl cyclase C (GC-C): regulation and signal transduction.

Authors:  Nirmalya Basu; Najla Arshad; Sandhya S Visweswariah
Journal:  Mol Cell Biochem       Date:  2009-12-04       Impact factor: 3.396

10.  Cross talk between receptor guanylyl cyclase C and c-src tyrosine kinase regulates colon cancer cell cytostasis.

Authors:  Nirmalya Basu; Rashna Bhandari; Vivek T Natarajan; Sandhya S Visweswariah
Journal:  Mol Cell Biol       Date:  2009-07-20       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.